<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Cks1 component of the SCF(Skp2) complex is necessary for p27(Kip1) ubiquitylation and degradation </plain></SENT>
<SENT sid="1" pm="."><plain>Cks1 expression is elevated in various B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously shown that loss of Cks1 results in elevated p27(Kip1) levels and delayed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development in a mouse model of Myc-induced B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Surprisingly, loss of Skp2 in the same mouse model also resulted in elevated p27(Kip1) levels but exhibited no impact on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This raises the possibility that Cks1 could have other oncogenic activities than suppressing p27(Kip1) </plain></SENT>
<SENT sid="5" pm="."><plain>To challenge this notion we have targeted overexpression of Cks1 to B cells using a conditional retroviral bone marrow transduction-transplantation system </plain></SENT>
<SENT sid="6" pm="."><plain>Despite potent ectopic overexpression, Cks1 was unable to promote <z:mp ids='MP_0005154'>B cell hyperproliferation</z:mp> or B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, indicating that Cks1 is not oncogenic when overexpressed in B cells </plain></SENT>
<SENT sid="7" pm="."><plain>Since Skp2 overexpression can drive T-cell <z:mp ids='MP_0002006'>tumorigenesis</z:mp> or other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> we also widened the quest for oncogenic activity of Cks1 by ubiquitously expressing Cks1 in hematopoetic progenitors </plain></SENT>
<SENT sid="8" pm="."><plain>At variance with c-Myc overexpression, which caused <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, Cks1 overexpression did not induce myeloproliferation or <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, despite being associated with a poor prognosis in various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, sole Cks1 expression is insufficient to induce <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or a <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> in vivo </plain></SENT>
</text></document>